Glencore (GLEN) has decided to maintain its primary listing in London, citing concerns over whether the group would be included within the S&P 500 index if it made the move to New York. The revelation ...

H1 sales growth for Novo Nordisk’s segment that includes Ozempic and Wegovy was down from the same period in 2024.